Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.

Saved in:
Bibliographic Details
Title: Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
Authors: Vaduganathan M; Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V., B.L.C., I.J.K., Z.M.M., A.S.D., S.D.S.)., Claggett BL; Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V., B.L.C., I.J.K., Z.M.M., A.S.D., S.D.S.)., Kulac IJ; Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V., B.L.C., I.J.K., Z.M.M., A.S.D., S.D.S.)., Miao ZM; Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V., B.L.C., I.J.K., Z.M.M., A.S.D., S.D.S.)., Desai AS; Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V., B.L.C., I.J.K., Z.M.M., A.S.D., S.D.S.)., Jhund PS; University of Glasgow, UK (P.S.J., A.D.H., J.J.V.M.)., Henderson AD; University of Glasgow, UK (P.S.J., A.D.H., J.J.V.M.)., Brinker M; Research & Development, Pharmaceuticals, Bayer, Berlin, Germany (M.B., J.L.-F., P.V., M.F.S., A.L.)., Lay-Flurrie J; Research & Development, Pharmaceuticals, Bayer, Berlin, Germany (M.B., J.L.-F., P.V., M.F.S., A.L.)., Viswanathan P; Research & Development, Pharmaceuticals, Bayer, Berlin, Germany (M.B., J.L.-F., P.V., M.F.S., A.L.)., Scheerer MF; Research & Development, Pharmaceuticals, Bayer, Berlin, Germany (M.B., J.L.-F., P.V., M.F.S., A.L.)., Lage A; Research & Development, Pharmaceuticals, Bayer, Berlin, Germany (M.B., J.L.-F., P.V., M.F.S., A.L.)., Lam CSP; National Heart Centre Singapore & Duke-National University of Singapore (C.S.P.L.)., Senni M; Papa Giovanni XXIII Hospital, University of Milano-Bicocca, Bergamo, Italy (M.S.)., Shah SJ; Northwestern University Feinberg School of Medicine, Chicago, IL (S.J.S.)., Voors AA; University of Groningen, Netherlands (A.A.V.)., Zannad F; University of Lorraine, Nancy, France (F.Z.)., Pitt B; University of Michigan, Ann Arbor (B.P.)., McMurray JJV; University of Glasgow, UK (P.S.J., A.D.H., J.J.V.M.)., Solomon SD; Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V., B.L.C., I.J.K., Z.M.M., A.S.D., S.D.S.).
Source: Circulation [Circulation] 2025 Jan 14; Vol. 151 (2), pp. 149-158. Date of Electronic Publication: 2024 Sep 28.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4539 (Electronic) Linking ISSN: 00097322 NLM ISO Abbreviation: Circulation Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1524-4539
DOI:10.1161/CIRCULATIONAHA.124.072055